Are certain individuals, such as women of reproductive age with conditions like diabetes, Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS), or compromised immune systems, more prone to fungal infections, including skin fungal infections and vaginal yeast infections?

Are Certain Individuals More Prone to Fungal Infections?

Yes, specific populations are significantly more susceptible to both systemic and mucosal fungal infections, including skin and vaginal yeast infections, with immunocompromised individuals, people with diabetes, and HIV/AIDS patients being at highest risk. 1, 2

High-Risk Populations

Immunocompromised Patients

• Patients with profound and prolonged neutropenia (particularly those with hematological malignancies) face the highest risk, with invasive candidiasis occurring in 12% of cases prior to routine azole prophylaxis. 1
• HIV/AIDS patients with CD4+ counts <200 cells/μL are at substantially increased risk for oropharyngeal candidiasis (OPC), with erythematous and pseudomembranous forms being predictive of progressive immunodeficiency. 1, 3
• Patients with CD4 counts <50 cells/μL represent the highest risk category for both developing candidiasis and harboring azole-resistant organisms. 4
• Transplant recipients and those on immunosuppressive therapy (including corticosteroids) have markedly elevated susceptibility to fungal infections due to compromised immune responses. 1, 5

Diabetic Patients

• Women with diabetes mellitus type 2 show significantly higher rates of vaginal yeast colonization (18.8% vs 11.8% in non-diabetics) and are more likely to be symptomatic (66.66% with VVC or recurrent VVC vs 33.33% colonized). 6
• Patients with poorly controlled glycemia are particularly prone to genital mycotic infections because high blood glucose levels promote yeast attachment, growth, and interfere with host immune responses. 2
• Diabetic patients face increased risk not only for incident infection but also for recurrence, underscoring the critical role of glycemic control. 2

Women-Specific Risk Factors

• Pregnancy, estrogen use, and oral contraceptive use increase susceptibility to vulvovaginal candidiasis. 2
• Women of reproductive age (25-34 years) show the highest prevalence of recurrent VVC (12%), with overall self-reported RVVC prevalence at 9%. 1
• Genetic predisposition may contribute to idiopathic recurrent VVC in some women. 1

Additional Risk Factors Across Populations

Medication-Related Risks

• Antibiotic use disrupts normal vaginal and oral flora, predisposing to Candida overgrowth. 1, 2
• Repeated and prolonged azole exposure, particularly in profoundly immunosuppressed patients, leads to acquired fluconazole resistance and emergence of non-albicans species (C. glabrata, C. krusei) with intrinsic reduced azole susceptibility. 1, 4, 3
• Inhaled corticosteroids increase risk of oral thrush. 3

Anatomical and Environmental Factors

• Breakdown of anatomical barriers (skin integrity, mucous membranes) represents a major risk factor for invasive fungal infections. 5
• Uncircumcised men are almost exclusively affected by Candida balanitis, as the moist, warm space underneath the foreskin promotes yeast growth, especially with poor hygiene. 2
• Obese patients are prone to intertrigo (skin fold infections) due to moisture and friction. 1

Behavioral and Healthcare-Associated Risks

• Intensive care unit patients with prolonged hospitalization, central venous catheters, and broad-spectrum antibiotic exposure face elevated risk. 5
• Radiation therapy to the head and neck increases oral thrush risk. 3
• Sexual behaviors including orogenital sex may increase VVC risk in women. 2

Clinical Implications and Pitfalls

Important Caveats

• Vulvovaginal candidiasis in HIV-infected women is often unrelated to HIV status and cannot alone be ascribed to advanced HIV disease, as it is common among healthy adult women (affecting three out of four at some point). 1, 7
• Recurrent VVC affects an estimated 6 million women in the United States, causing approximately $4.7 billion in lost productivity annually, making it a significant public health issue beyond just immunocompromised populations. 1
• The vaginal pH environment (pH 4) significantly affects antifungal efficacy, with MICs being substantially higher at normal vaginal pH compared to laboratory testing conditions (pH 7), particularly for terconazole against C. glabrata (>388-fold difference). 1

Resistance Patterns to Monitor

• C. glabrata can cause refractory mucosal candidiasis particularly in patients with advanced immunosuppression and is less susceptible to conventional azole therapy despite being less virulent. 1, 2
• Following HAART introduction in HIV patients, there has been a dramatic decline in refractory disease and resistant Candida isolates, with 93% of isolates remaining fluconazole-susceptible. 1
• Multiple courses of therapy or suppressive therapy for recurrent infection are major risk factors for developing azole-refractory infections. 1